SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

A blood atlas of COVID-19 defines hallmarks of disease severity and specificity.

COvid-19 Multi-omics Blood ATlas (COMBAT) Consortium (2022) A blood atlas of COVID-19 defines hallmarks of disease severity and specificity. Cell, 185 (5). 916-938.e58. ISSN 1097-4172 https://doi.org/10.1016/j.cell.2022.01.012
SGUL Authors: Bicanic, Tihana

[img]
Preview
PDF Published Version
Available under License Creative Commons Attribution.

Download (28MB) | Preview
[img] Microsoft Excel (Table S1) Published Version
Available under License Creative Commons Attribution.

Download (15kB)
[img]
Preview
PDF (Table S2) Published Version
Available under License Creative Commons Attribution.

Download (753kB) | Preview
[img] Microsoft Excel (Table S3) Published Version
Download (22kB)
[img] Microsoft Excel (Table S4) Published Version
Available under License Creative Commons Attribution.

Download (2MB)
[img]
Preview
PDF (Data S1) Published Version
Available under License Creative Commons Attribution.

Download (318kB) | Preview
[img]
Preview
PDF (Data S2) Published Version
Available under License Creative Commons Attribution.

Download (2MB) | Preview
[img]
Preview
PDF (Data S3) Published Version
Available under License Creative Commons Attribution.

Download (16MB) | Preview
[img]
Preview
PDF (Data S4) Published Version
Available under License Creative Commons Attribution.

Download (12MB) | Preview
[img]
Preview
PDF (Data S5) Published Version
Available under License Creative Commons Attribution.

Download (2MB) | Preview
[img]
Preview
PDF (Data S6) Published Version
Available under License Creative Commons Attribution.

Download (2MB) | Preview

Abstract

Treatment of severe COVID-19 is currently limited by clinical heterogeneity and incomplete description of specific immune biomarkers. We present here a comprehensive multi-omic blood atlas for patients with varying COVID-19 severity in an integrated comparison with influenza and sepsis patients versus healthy volunteers. We identify immune signatures and correlates of host response. Hallmarks of disease severity involved cells, their inflammatory mediators and networks, including progenitor cells and specific myeloid and lymphocyte subsets, features of the immune repertoire, acute phase response, metabolism, and coagulation. Persisting immune activation involving AP-1/p38MAPK was a specific feature of COVID-19. The plasma proteome enabled sub-phenotyping into patient clusters, predictive of severity and outcome. Systems-based integrative analyses including tensor and matrix decomposition of all modalities revealed feature groupings linked with severity and specificity compared to influenza and sepsis. Our approach and blood atlas will support future drug development, clinical trial design, and personalized medicine approaches for COVID-19.

Item Type: Article
Additional Information: © 2022 The Author. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Keywords: COVID-19, SARS-CoV-2, blood, coronavirus, epigenetics, immune, multi-omics, personalized medicine, proteomics, transcriptomics, Adult, Biomarkers, Blood Proteins, COVID-19, Cell Cycle Proteins, Female, Humans, Influenza, Human, Lymphocytes, Machine Learning, Male, Middle Aged, Mitogen-Activated Protein Kinase 14, Monocytes, Principal Component Analysis, Proteome, SARS-CoV-2, Sepsis, Severity of Illness Index, Transcription Factor AP-1, COvid-19 Multi-omics Blood ATlas (COMBAT) Consortium. Electronic address: julian.knight@well.ox.ac.uk, COvid-19 Multi-omics Blood ATlas (COMBAT) Consortium, Lymphocytes, Monocytes, Humans, Sepsis, Mitogen-Activated Protein Kinase 14, Blood Proteins, Cell Cycle Proteins, Proteome, Transcription Factor AP-1, Severity of Illness Index, Principal Component Analysis, Adult, Middle Aged, Female, Male, Influenza, Human, Biomarkers, Machine Learning, COVID-19, SARS-CoV-2, 06 Biological Sciences, 11 Medical and Health Sciences, Developmental Biology
SGUL Research Institute / Research Centre: Academic Structure > Infection and Immunity Research Institute (INII)
Journal or Publication Title: Cell
ISSN: 1097-4172
Language: eng
Dates:
DateEvent
3 March 2022Published
21 January 2022Published Online
17 January 2022Accepted
Publisher License: Creative Commons: Attribution 4.0
Projects:
Project IDFunderFunder ID
204290/Z/16/ZWellcome Trusthttp://dx.doi.org/10.13039/100004440
MC_UU_00008/10Medical Research Councilhttp://dx.doi.org/10.13039/501100000265
MR/S005471/1Medical Research Councilhttp://dx.doi.org/10.13039/501100000265
R24 DK106766NIDDK NIH HHSUNSPECIFIED
UNSPECIFIEDWellcome Trusthttp://dx.doi.org/10.13039/100004440
22252Versus ArthritisUNSPECIFIED
RG/13/9/303269British Heart Foundationhttp://dx.doi.org/10.13039/501100000274
FS/18/63/34184British Heart Foundationhttp://dx.doi.org/10.13039/501100000274
2018-I2M-2-002CAMS IFMSUNSPECIFIED
C130623/A249471Cancer Research UKhttp://dx.doi.org/10.13039/501100000289
EP/R018472/1Engineering and Physical Sciences Research Councilhttp://dx.doi.org/10.13039/501100000266
EP/R005125/1Engineering and Physical Sciences Research Councilhttp://dx.doi.org/10.13039/501100000266
EP/T001968/1Engineering and Physical Sciences Research Councilhttp://dx.doi.org/10.13039/501100000266
KENN151612Kennedy Trust for Rheumatology ResearchUNSPECIFIED
KENN192004Kennedy Trust for Rheumatology ResearchUNSPECIFIED
KENN171803Kennedy Trust for Rheumatology ResearchUNSPECIFIED
MCUU00016/14Medical Research Councilhttp://dx.doi.org/10.13039/501100000265
12009/14Medical Research Councilhttp://dx.doi.org/10.13039/501100000265
MR/S035850/1Medical Research Councilhttp://dx.doi.org/10.13039/501100000265
MCPC19059Medical Research Councilhttp://dx.doi.org/10.13039/501100000265
U192U19AI082630National Institutes of Healthhttp://dx.doi.org/10.13039/100000002
R35579/AA002/M85-F2Rosetrees Trusthttp://dx.doi.org/10.13039/501100000833
RGF\EA\201074Royal Societyhttp://dx.doi.org/10.13039/501100000288
UF150238Royal Societyhttp://dx.doi.org/10.13039/501100000288
MR/S005471/1Medical Research CouncilUNSPECIFIED
106130/Z/14/ZWellcome Trusthttp://dx.doi.org/10.13039/100004440
109965MAWellcome Trusthttp://dx.doi.org/10.13039/100004440
107212/A/15/ZWellcome Trusthttp://dx.doi.org/10.13039/100004440
201488/Z/16/ZWellcome Trusthttp://dx.doi.org/10.13039/100004440
203141/Z/16/ZWellcome Trusthttp://dx.doi.org/10.13039/100004440
204826/Z/16/ZWellcome Trusthttp://dx.doi.org/10.13039/100004440
204969/Z/16/ZWellcome Trusthttp://dx.doi.org/10.13039/100004440
205228/Z/16/ZWellcome Trusthttp://dx.doi.org/10.13039/100004440
206194Wellcome Trusthttp://dx.doi.org/10.13039/100004440
4-SRA-2017-473-A-AWellcome Trusthttp://dx.doi.org/10.13039/100004440
211276/B/18/ZWellcome Trusthttp://dx.doi.org/10.13039/100004440
215097/Z/18/ZWellcome Trusthttp://dx.doi.org/10.13039/100004440
220171/Z/20/ZWellcome Trusthttp://dx.doi.org/10.13039/100004440
PubMed ID: 35216673
Web of Science ID: WOS:000768271800002
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/114235
Publisher's version: https://doi.org/10.1016/j.cell.2022.01.012

Actions (login required)

Edit Item Edit Item